Valneva Secures UK Approval for World’s First Chikungunya Vaccine, IXCHIQ®

Valneva SE , a specialty vaccine company, announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing author...

February 05, 2025 | Wednesday | News
Zoetis Updates U.S. Label for Librela® (bedinvetmab) Following Post-Approval Experience

Zoetis Inc. announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission of a supplement to the U.S...

February 05, 2025 | Wednesday | News
Grifols Partners with FcR Therapeutics to Develop Nanobodies for Autoimmune Disease Treatment

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines,  announced that it is col...

February 05, 2025 | Wednesday | News
AstraZeneca’s Imfinzi® Receives Positive CHMP Recommendation for Limited-Stage Small Cell Lung Cancer Treatment in the EU

AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults ...

February 05, 2025 | Wednesday | News
Vanda Pharmaceuticals and AnaptysBio Enter Exclusive Global License Agreement for Imsidolimab in GPP Treatment

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) announced an exclusive, global license agreement ...

February 04, 2025 | Tuesday | News
Halozyme's Subcutaneous RYBREVANT® Formulation Receives Positive CHMP Opinion for Advanced NSCLC Treatment

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a...

February 04, 2025 | Tuesday | News
Eisai and Biogen Provide Update on Lecanemab’s EU Regulatory Review for Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

February 04, 2025 | Tuesday | News
EMA's CHMP Recommends Opdivo® + Yervoy® for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

 Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

February 03, 2025 | Monday | News
European Commission Approves Vocabria + Rekambys for HIV Treatment in Adolescents Aged 12 and Older

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, ...

February 03, 2025 | Monday | News
Merck's CAPVAXIVE™ Pneumococcal Vaccine Receives Positive CHMP Recommendation for Approval in the European Union

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced  that the Committee for Medicinal Products for Human Use (CHMP) of ...

February 03, 2025 | Monday | News
Amgen Announces European Commission Approval of BLINCYTO® for Frontline Treatment of B-ALL

Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has approved BLINCYTO® (blinatumomab) monotherapy as part of consolidation therapy...

January 31, 2025 | Friday | News
GSK's Depemokimab Accepted for EMA Review in Asthma and Chronic Rhinosinusitis with Nasal Polyps

GSK plc (LSE/NYSE: GSK) announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemok...

January 29, 2025 | Wednesday | News
Roche Announces Positive Overall Survival Results for Itovebi™ in Advanced Breast Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating...

January 29, 2025 | Wednesday | News
Upperton Pharma Solutions Expands with New Sterile Manufacturing Facility in Nottingham

Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of its new sterile manufacturing...

January 28, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close